[Calenduloside E inhibits hepatocellular carcinoma cell proliferation and migration by down-regulating GPX4 and

Q Chen1,2, S Shang1,2,3, H Lu1,2

  • 1Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Wannan Medical College, Wuhu 241002, China.

Abstract

Insights

Calenduloside E inhibits hepatocellular carcinoma (HCC) cell growth and spread by reducing GPX4 and SLC7A11 levels through the autophagy pathway, offering a potential new therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Context:

  • Hepatocellular carcinoma (HCC) is a significant global health concern with limited treatment options.
  • Understanding the molecular mechanisms underlying HCC progression is crucial for developing targeted therapies.

Purpose:

  • To elucidate the molecular mechanism by which calenduloside E inhibits HCC cell proliferation and migration.
  • To investigate the role of GPX4, SLC7A11, and the autophagy pathway in calenduloside E's anti-cancer effects.

Summary:

  • Calenduloside E demonstrated significant inhibition of HCC cell viability, proliferation, and migration.
  • The compound down-regulated the expression of GPX4 and SLC7A11, proteins highly expressed in HCC and correlated with poor survival.
  • These effects were mediated through the autophagy pathway, involving the Akt-mTOR signaling cascade.

Impact:

  • This study reveals a novel mechanism of action for calenduloside E in HCC.
  • The findings suggest calenduloside E as a potential therapeutic agent for HCC, targeting GPX4, SLC7A11, and autophagy.